The Efficacy and Safety of Once-daily Fluticasone Furoate/Umeclidinium/Vilanterol Versus Twice-daily Budesonide/Formoterol in a Subgroup of Patients from China with Symptomatic COPD at Risk of Exacerbations (FULFIL Trial)WOS

    Cited by: 0|Bibtex|11|

    COPD, 2018, Pages 1-7.

    Keywords:
    ChinaGSK study CTT116853NCT02345161health-related quality of lifelung functionview more (1+)

    Abstract:

    The FULFIL study evaluated once-daily fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) 100 µg/62.5 µg/25 µg versus twice-daily budesonide/formoterol (BUD/FOR) 400 µg/12 µg in patients with symptomatic COPD at risk of exacerbations. FULFIL demonstrated clinically meaningful and statistically significant improvements at Week 24 in t...More
    Your rating :
    0

     

    Tags
    Comments